文献速递糖尿病

新发1型糖尿病抗病毒治疗后的三年随访:糖尿病病毒检测与干预试验结果

Three-Year Follow-up After Antiviral Treatment in New-Onset Type 1 Diabetes: Results From the Diabetes Virus Detection and Intervention Trial.
PubMed 文献 · Diabetes Care · 2025-01-01

糖尿病病毒检测与干预试验显示,普可那利联合利巴韦林抗病毒治疗在1型糖尿病诊断后1年较安慰剂减少内源性C肽下降。本文报告诊断后2年和3年结果:96例6-15.9岁新诊断患儿随机1:1接受6个月治疗或安慰剂,随访3年,3年时75例随访,两组C肽AUC无统计学显著差异,抗病毒治疗带来的C肽下降减缓在2年或3年后不再存在。

要点

  • 抗病毒治疗(普可那利联合利巴韦林)在1型糖尿病诊断后1年较安慰剂减少内源性C肽下降。
  • 2年时安慰剂组C肽AUC均值±SD为0.27±0.33,普可那利联合利巴韦林组为0.34±0.37。
  • 3年时两组C肽AUC分别降至0.17±0.23和0.25±0.34,无统计学显著差异,次要终点亦相当。

核心结论

  • 抗病毒治疗后C肽水平下降减缓在2年或3年后不再存在。
  • 需要进一步研究以探索抗病毒治疗用于1型糖尿病预防和治疗的选择。

研究设计与样本

  • 多中心、随机、安慰剂对照(1:1)试验,纳入96例6-15.9岁新诊断1型糖尿病儿童和青少年。
  • 从诊断起给予抗病毒治疗(普可那利联合利巴韦林)或安慰剂6个月,随访3年。
  • 主要结局为残余C肽分泌,以2小时混合餐耐量试验评估的曲线下面积(AUC)报告;次要结局包括胰岛素剂量和HbA1c。

主要发现

  • 3年随访时75例参与者到场。
  • 2年时安慰剂组C肽AUC均值±SD为0.27±0.33,普可那利联合利巴韦林组为0.34±0.37。
  • 3年后AUC分别降至0.17±0.23和0.25±0.34。
  • 两组间无统计学显著差异。
  • 两组在次要终点方面亦相当。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要进一步研究以探索抗病毒治疗用于1型糖尿病预防和治疗的选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In the Diabetes Virus Detection and Intervention trial, antiviral treatment with pleconaril and ribavirin decreased the decline, compared with placebo, in endogenous C-peptide 1 year after diagnosis of type 1 diabetes (T1D) in children and adolescents. This article reports the results 2 and 3 years after diagnosis. RESEARCH DESIGN AND METHODS: This was a multicenter, randomized, placebo-controlled (1:1) trial of 96 children and adolescents aged 6-15.9 years newly diagnosed with T1D. Antiviral treatment (pleconaril and ribavirin) or placebo was given for 6 months from diagnosis, and participants were followed for 3 years. The primary outcome was residual C-peptide secretion, reported as the area under the curve (AUC), assessed by 2-h mixed-meal tolerance test. Secondary outcomes included insulin doses and HbA1c. RESULTS: At the 3-year follow-up, 75 participants attended. At 2 years, the mean ± SD AUC for C-peptide in the placebo group was 0.27 ± 0.33 compared with 0.34 ± 0.37 in the pleconaril and ribavirin group. After 3 years, the AUC had decreased to 0.17 ± 0.23 and 0.25 ± 0.34, respectively. There was no statistically significant difference between the groups. The groups were also comparable with regard to secondary end points. CONCLUSIONS: The decreased reduction in C-peptide levels after antiviral treatment is no longer present after 2 or 3 years. Further investigations are needed to explore options to use antiviral treatment in the prevention and treatment of T1D.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Mynarek IM, Krogvold L, Mørk FB, et al. Three-Year Follow-up After Antiviral Treatment in New-Onset Type 1 Diabetes: Results From the Diabetes Virus Detection and Intervention Trial. Diabetes Care. 2025. PMID: 39804800. doi:10.2337/dc24-2121

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。